home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

242 rows where filing_period = "second_quarter", filing_year = 2016 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 242 ✖

filing_year 1

  • 2016 · 242 ✖

filing_period 1

  • second_quarter · 242 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1836727 AMERICAN COLLEGE OF CLINICAL PHARMACY 0edeb597-7089-4032-a4b9-a64567211685 Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2016 second_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   128875 0 0 2016-06-27T14:58:27.203000-04:00
1836741 NAHIGIAN STRATEGIES, LLC afcce0f2-b73c-43bb-8a0c-5332cacb37ba Q2 NAHIGIAN STRATEGIES, LLC 322897 TEVA PHARMACEUTICALS USA INC 2016 second_quarter PHA Advocate for pathway to improving existing therapies.   45000   0 0 2016-06-28T13:57:51.087000-04:00
1837009 HANCE SCARBOROUGH 6a44c87a-f5ba-4cc7-b1a4-8ddd8de002d7 Q2 HANCE SCARBOROUGH 17443 ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS 2016 second_quarter PHA Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs. HOUSE OF REPRESENTATIVES,SENATE     0 0 2016-07-01T13:22:21.393000-04:00
1837045 PD FRAZER CONSULTING, INC. f53c32dd-e611-4410-8ebc-5ef5b03cd8b4 Q2 PD FRAZER CONSULTING, INC. 65998 CANADA INTERNATIONAL PHARMACY ASSOCIATION 2016 second_quarter PHA Monitor the development of proposed bills about the importation of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-07-01T14:18:17.867000-04:00
1837069 AMERICAN AMBULANCE ASSOCIATION 37a058e5-535b-475f-9603-c1ccd29671e0 Q2 AMERICAN AMBULANCE ASSOCIATION 56018 AMERICAN AMBULANCE ASSOCIATION 2016 second_quarter PHA Lobbied in support of the Protecting Patient Access to Emergency Medications Act (H.R. 4365, S. 2932) to ensure the continuity of standing orders for the administration of certain controlled substances by paramedics and EMTs to patients. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   300000 0 0 2016-07-01T15:29:10.813000-04:00
1837920 MR. BRIAN KELLY b69a4444-d0f5-4d0a-8e27-16042cd3ba03 Q2 MR. BRIAN KELLY 40024191 LUNDBECK PHARMACEUTICALS 2016 second_quarter PHA FDA Reform HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2016-07-06T18:12:37.517000-04:00
1838112 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) a1cab4c7-5f09-4571-b66d-b6c9090550b6 Q2 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 400265214 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 2016 second_quarter PHA Issues related to pharmaceutical pricing and federal oversight by the FDA Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   198893 0 0 2016-07-07T12:04:14.517000-04:00
1838174 KATE MOSS f9bc1983-2b02-47fe-a05d-f19aea135280 Q2 KATE MOSS 25988 CVS HEALTH 2016 second_quarter PHA Issues related to prescription drug abuse and drug supply chain safety. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-07-07T13:31:54.167000-04:00
1838506 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 067682ad-7584-4460-9eb3-e84d9656dffb Q2 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2016 second_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   270000 0 0 2016-07-08T10:58:29.223000-04:00
1838595 PARRY, ROMANI, DECONCINI & SYMMS cb572958-310d-46a2-bacf-eb8efd1f28ee Q2 PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2016 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 18000   0 0 2016-07-08T12:32:19.500000-04:00
1838605 ROCK & ASSOCIATES 94228fcc-3f31-4b39-a180-1405611a36e2 Q2 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2016 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-07-08T12:50:37.927000-04:00
1838616 ROCK & ASSOCIATES ddf4d1f3-b7ce-43ea-b76b-d1493d69a6de Q2 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2016 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-07-08T12:55:53.877000-04:00
1838621 ROCK & ASSOCIATES 03f44bee-dcea-4949-a095-ae3655093cb0 Q2 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2016 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-07-08T12:58:56.457000-04:00
1838623 ROCK & ASSOCIATES d0891db2-677d-4b9c-bf26-5cf452e5b46a Q2 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2016 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-07-08T13:02:58.443000-04:00
1838630 ROCK & ASSOCIATES b6774d34-19ae-4eac-899b-4023271eacff Q2 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2016 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-07-08T13:11:05.160000-04:00
1838648 ROCK & ASSOCIATES 0cfb999b-919a-4979-9100-ecbffebe6bdf Q2 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2016 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-07-08T13:24:24.133000-04:00
1838826 HOLLAND & KNIGHT LLP 15d2dfeb-e74b-473a-85f6-89cf4bedf214 Q2 HOLLAND & KNIGHT LLP 18466 PROTECTING ACCESS TO PAIN RELIEF COALITION 2016 second_quarter PHA Advocating for policy to ensure patient access to pain relief. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-07-08T17:02:50.110000-04:00
1838829 HOLLAND & KNIGHT LLP b595a7cf-194b-4146-87f4-3b6057207002 Q2 HOLLAND & KNIGHT LLP 18466 THE BIOSIMILARS FORUM 2016 second_quarter PHA Medicare reimbursement issues, FDA regulation of biosimilars. HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2016-07-08T17:06:56.063000-04:00
1838967 INDEPENDENT PHARMACY COOPERATIVE 7fe05fd2-dd12-403a-a959-27dd10834c16 Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2016 second_quarter PHA H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas. H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas. S.524 Comprehensive Addiction and Recovery Act of 2016. IPC is against as currently written. Actual Acquisition Cost (AAC) adoption with state Medicaid programs. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2016-07-10T12:56:24.813000-04:00
1839311 RED+BLUE STRATEGIES c92f3e28-6271-47f0-af4f-4fbcbc64c226 Q2 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2016 second_quarter PHA National Defense Authorization Act of FY 2017 - Work to ensure that the current treatment of mail order for retired and active military personnel and their families remains constant in the pending Authorization bill. The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction. The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies. Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Issues related to mail order coverage for Medicare, Medicaid, Exchanges, Tricare and other programs. Issues related to the pricing of prescription medications. Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. Issues related to the treatment of pharmacy benefit managers in federal programs. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Issues related to access and affordability for prescription medications for both government and private sector benefit programs. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-07-11T14:43:45.277000-04:00
1839415 RED+BLUE STRATEGIES df4dd265-b009-4528-b14f-b06f301631e1 Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2016 second_quarter PHA The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction. H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits. The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies. H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies. Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-07-11T15:38:54.563000-04:00
1840272 THORSEN FRENCH ADVOCACY LLC 6b759bb6-a087-42f9-ab1a-86635b13acd5 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 CARDINAL HEALTH, INC. 2016 second_quarter PHA Issues related to prescription drug abuse. Issues related to pharmaceutical market value. S.524: Comprehensive Addiction and Recovery Act (CARA). HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-07-12T14:48:24.890000-04:00
1840298 THORSEN FRENCH ADVOCACY LLC 390ad1ff-13e1-4742-bae5-bffb3566c217 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2016 second_quarter PHA Issues related to pharmaceutical market value. Issues related to prescription drug abuse. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-12T15:05:59.347000-04:00
1840322 NELSON MULLINS RILEY & SCARBOROUGH e7a63a14-eaf9-4675-a7d0-42b90d1adb69 Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) 2016 second_quarter PHA Any legislation and regulation to the treatment of opioid abuse. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-07-12T15:12:12.267000-04:00
1840666 THORSEN FRENCH ADVOCACY LLC 175aa0d4-5f00-4bed-ad56-6b964efc3b5f Q2 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2016 second_quarter PHA General issues related to prescription drug abuse. Issues related to pharmaceutical market value. S.483: Ensuring Patient Access and Effective Drug Enforcement Act of 2016. H.R.471: Ensuring Patient Access and Effective Drug Enforcement Act of 2016. S. 524: Comprehensive Addiction and Recovery Act of 2016. H.R. 953: Comprehensive Addiction and Recovery Act of 2016. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-07-13T09:33:39.750000-04:00
1840758 FLYNN & ASSOCIATES, INC. d35fda00-a374-4a52-b698-547e2c9a9ddb Q2 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2016 second_quarter PHA Medicare Part-D rebates Trade agreements Patent reform issues Medicare Part-B Doctor reimbursement regulations HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-07-13T10:21:57.317000-04:00
1841487 CONNECT 4 STRATEGIES, LLC b9b8bdfe-04f0-4c96-a1b2-d6f632ab7648 Q2 CONNECT 4 STRATEGIES, LLC 401103720 BIOMARIN PHARMACEUTICAL INC. 2016 second_quarter PHA Rare pediatric review voucher. S 1878 and HR 1537 Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-07-13T21:01:52.910000-04:00
1841915 WILLIAMS AND JENSEN, PLLC 058222fb-b5c3-4eca-9b46-8cf0a5a2034e Q2 WILLIAMS AND JENSEN, PLLC 41454 FAGRON NORTH AMERICA 2016 second_quarter PHA Issues related to Drug Quality and Security Act (DQSA) and Pharmacy compounding. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-14T11:35:49.890000-04:00
1841984 MCDERMOTT+ LLC adb2ce76-5651-4f15-a586-741c83779771 Q2 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2016 second_quarter PHA Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-07-14T11:57:51.393000-04:00
1842024 MCDERMOTT+ LLC a0e57cb3-ec2c-4abb-b077-effb0b7aa92f 2A MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2016 second_quarter PHA Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-07-14T12:10:29.833000-04:00
1842929 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 9680354d-7e7e-4a06-bc39-ce241c59e169 Q2 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2016 second_quarter PHA Proposals relating to the regulation of direct to consumer prescription drug advertising H.R. 4565, Responsibility in Drug Advertising Act of 2016, to prohibit for three years after FDA approval direct to consumer prescription drug advertising Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE   420000 0 0 2016-07-15T09:53:22.737000-04:00
1842936 POWERS PYLES SUTTER & VERVILLE, P.C. eb5d011a-1123-4586-9209-15be2eb320ae Q2 POWERS PYLES SUTTER & VERVILLE, P.C. 32008 340B HEALTH 2016 second_quarter PHA Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3) funding of the Health Resources and Services Administration (HRSA)under the Labor Health & Human Services & Education appropriations bills. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-15T09:53:24.817000-04:00
1843030 ACADEMY OF MANAGED CARE PHARMACY 26eae006-e062-4964-a08c-89ae33cdd346 Q2 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2016 second_quarter PHA Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule. Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   188000 0 0 2016-07-15T10:33:58.977000-04:00
1843052 KENT & O'CONNOR, INC. 238b9bf1-a7e0-4a5d-a311-49361bcd5c40 Q2 KENT & O'CONNOR, INC. 21426 INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION 2016 second_quarter PHA Legislation and regulations relating to drug and safety issues. Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection 30000   0 0 2016-07-15T10:39:21.180000-04:00
1843093 WAXMAN STRATEGIES ff107c8f-167c-4df4-99d2-a1497d15b528 Q2 WAXMAN STRATEGIES 401103693 340B HEALTH 2016 second_quarter PHA Laws and regulations affecting the 340B Drug Discount Program Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,White House Office 18750   0 0 2016-07-15T10:45:51.807000-04:00
1843184 CAPVIEW ASSOCIATES LLC (DBA CAPVIEW STRATEGIES) b252cdbe-f441-422f-97c0-b2df93b77a9e Q2 CAPVIEW ASSOCIATES LLC (DBA CAPVIEW STRATEGIES) 401103546 PFIZER INC. 2016 second_quarter PHA Issues related to the value of pharmaceuticals including developing sustainable models that support innovation. Centers For Medicare and Medicaid Services (CMS),Medicare Payment Advisory Commission (MedPAC) 20000   0 0 2016-07-15T11:13:22.980000-04:00
1843475 NELSON MULLINS RILEY & SCARBOROUGH 6cedafc4-aba2-4fe8-b2f0-74749f3861af Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 CASCADE HEMOPHILIA CONSORTIUM 2016 second_quarter PHA Issues related to 340B Drug Pricing Progam HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-07-15T12:42:01.053000-04:00
1843771 WINNING STRATEGIES WASHINGTON 8bf8a1f1-237c-4134-b6c5-c08b6d353ca4 Q2 WINNING STRATEGIES WASHINGTON 50796 KALEO 2016 second_quarter PHA Pharmaceutical drug development, Reducing opiod overdose deaths and S. 707; H.R. 3680 provisions related to Nalaxone; S. 2256 provisions related to Nalaxone HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-15T14:13:01.570000-04:00
1844049 NELSON MULLINS RILEY & SCARBOROUGH 6a911653-7b83-4124-b1f3-45d6e38bd5b6 Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2016 second_quarter PHA Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-07-15T15:26:18.627000-04:00
1844188 CARD & ASSOCIATES, LLC 4bb7de4c-7320-4147-800d-ad220cbd7f11 Q2 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2016 second_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2016-07-15T15:42:13.287000-04:00
1844243 CARD & ASSOCIATES, LLC 3e18eb93-42ef-4b88-bcac-fd435ad41115 2T CARD & ASSOCIATES, LLC 84217 CLOAKROOM ADVISORS LLC ON BEHALF OF LINDEN CARE LLC 2016 second_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers HOUSE OF REPRESENTATIVES,SENATE 15000   0 1 2016-07-15T15:49:18.037000-04:00
1844367 BLUECROSS BLUESHIELD OF TENNESSEE a9543602-fd43-4782-acbb-685e43d3524e Q2 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2016 second_quarter PHA General Pharmacy Issues; HR6, 21st Century Cures; opioid abuse (S. 524); specialty drug pricing Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2016-07-15T16:26:30.650000-04:00
1844616 COVINGTON & BURLING LLP ce47f067-bc7b-44cb-a8bd-357aa78c16b3 Q2 COVINGTON & BURLING LLP 11195 MEDIMETRIKS PHARMACEUTICALS INC 2016 second_quarter PHA Regulation of marketed unapproved drugs HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-07-15T19:13:18.887000-04:00
1844617 COVINGTON & BURLING LLP 1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32 Q2 COVINGTON & BURLING LLP 11195 FABRE-KRAMER PHARMACEUTICALS, INC 2016 second_quarter PHA Policy regarding demonstration of effectiveness for new drug approvals. HOUSE OF REPRESENTATIVES,SENATE     0 0 2016-07-15T19:14:22.717000-04:00
1844630 OREGON HEALTH & SCIENCE UNIVERSITY ebf9c8c4-e988-4551-898c-5580efeb180e Q2 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2016 second_quarter PHA 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2016-07-15T19:24:35.170000-04:00
1844663 THE D MAJOR GROUP a22c820a-8458-4203-9ef5-d6d90e37017f Q2 THE D MAJOR GROUP 401103162 CVS CAREMARK 2016 second_quarter PHA Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-16T09:14:44.140000-04:00
1845234 ALKERMES, INC. 5aca04a8-7bf2-47cb-8c10-2a1686d0b609 Q2 ALKERMES, INC. 400458235 ALKERMES, INC. 2016 second_quarter PHA Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 6 the 21st Century Cures Act Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   1340000 0 0 2016-07-18T10:25:12.713000-04:00
1845271 RED+BLUE STRATEGIES 29732d19-0f0c-4fe8-a3b3-62513dc9db88 Q2 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2016 second_quarter PHA S. 524 - The Comprehensive Addiction and Recovery Act - supporting efforts to fight opioid abuse in the United States. Work focused on the inclusion of "lock in" programs in the Medicare program to prevent and protect seniors from opioid addiction. S.185 - The Promise for Antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public. S. 2153 - Provider Payment Sunshine Act - policies supporting the inclusion of all prescribers to the Open Payments program. H.R. 5054 - Agriculture Appropriations Bill for FY 2017 - Issues related to FDA treatment of antibiotics and compounding of certain pharmaceuticals. Legislative and regulatory issues surrounding unique device identifiers (UDI) being addressed by CMS, FDA and ONC. Advancing provisions to highlight Antibiotic Innovation and combating prescription drug abuse in the President's FY 2017 budget. Supporting policies to maintain the integrity of laws regarding compounding of certain medications. Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid. Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-07-18T10:31:34.363000-04:00
1845765 CHAMBER HILL STRATEGIES 80764e92-5bdb-46a4-9eb2-5f26396bb603 Q2 CHAMBER HILL STRATEGIES 400645947 AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL) 2016 second_quarter PHA Implementation issues related to P.L. 113-54, the Drug Quality and Security Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-07-18T11:51:36.337000-04:00
1845846 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. c6868ce5-938c-4f8f-b021-4cf89838e1c3 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2016 second_quarter PHA HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2016-07-18T12:06:04.823000-04:00
1845867 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. df1bc0ee-9d61-4d2f-9fe7-2f3f16a94444 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2016 second_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE 50000   0 0 2016-07-18T12:08:20.573000-04:00
1845872 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 7af41366-5d63-457b-bc86-31e38d0c86b5 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2016 second_quarter PHA issues related to the 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-18T12:09:26.493000-04:00
1845880 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. b1df74f8-65ed-4a00-a8df-ddeeb1872fd7 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2016 second_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2016-07-18T12:10:31.277000-04:00
1845943 UNIVERSITY OF IOWA 54b8b8c6-6f22-4e9d-bf68-2635c76fd979 Q2 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2016 second_quarter PHA Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)   86662 0 0 2016-07-18T12:19:28.590000-04:00
1846275 JOHNS HOPKINS UNIVERSITY 74c4656e-2819-4e66-bded-ba00d8691c3f Q2 JOHNS HOPKINS UNIVERSITY 20664 JOHNS HOPKINS UNIVERSITY 2016 second_quarter PHA Pharmaceutical drug price increases; 340B drug discount program Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   100000 0 0 2016-07-18T13:25:09.723000-04:00
1846512 THE INGRAM GROUP LLC 665dc021-2621-4551-848a-e77b9cebc5cf Q2 THE INGRAM GROUP LLC 400577737 ELI LILLY AND COMPANY 2016 second_quarter PHA S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2015. H.R.6, 21st Century Cures Act. General issues related to the biopharmaceutical and pharmaceutical industries. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-07-18T14:05:33.757000-04:00
1846758 MASSACHUSETTS MEDICAL SOCIETY 8489cc49-dc25-47b5-ab37-654505d1199a Q2 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2016 second_quarter PHA Prescription Drug Pricing - no specific bill Direct to Consumer Advertising - no specific bill Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA)   80000 0 0 2016-07-18T15:27:09.190000-04:00
1846855 UNIVERSITY OF PITTSBURGH MEDICAL CENTER 2dcba39b-15ae-4b86-ad11-dfe92b69b013 Q2 UNIVERSITY OF PITTSBURGH MEDICAL CENTER 32065 UNIVERSITY OF PITTSBURGH MEDICAL CENTER 2016 second_quarter PHA Urge Congress to oppose cuts to the 340B program and address the escalation in drug prices. HOUSE OF REPRESENTATIVES,SENATE   250000 0 0 2016-07-18T15:52:37.757000-04:00
1847189 SAFEWAY INC. 6af08e0d-e1ba-453a-88ec-277e74ddd1d7 Q2 SAFEWAY INC. 300173 SAFEWAY 2016 second_quarter PHA H.R. 592/S. 314, Pharmacy and Underserved Areas Enhancement Act, all provisions. H.R. 4909, FY 2017 National Defense Authorization Act, provisions related to TRICARE and pharmacy access. H.R. 953/S. 524, Comprehensive Addition and Recovery Act, provisions related to state prescription drug monitoring programs. H.R. 793/S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015, all provisions. H.R. 3250, DXM Abuse Prevention Act, provisions related to retail pharmacy. HOUSE OF REPRESENTATIVES,SENATE   150000 0 0 2016-07-18T17:02:25.027000-04:00
1847427 ACG ADVOCACY 63a376a9-d468-4e89-b5d0-42394adfb994 Q2 ACG ADVOCACY 2057 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2016 second_quarter PHA Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-07-18T17:44:40.753000-04:00
1847438 PRIME POLICY GROUP f20dbb44-0013-4986-bbca-0df65bd1e620 Q2 PRIME POLICY GROUP 400532589 GLAXOSMITHKLINE 2016 second_quarter PHA Drug Pricing HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 40000   0 0 2016-07-18T17:47:59.330000-04:00
1847598 APOTEX CORP. fd7695bd-07d2-4194-9dda-61ae50c12fb5 Q2 APOTEX CORP. 310973 APOTEX CORP. 2016 second_quarter PHA H.R. 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S. 3056, the CREATES Act, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; Federal policy relating to the approval of pending abbreviated new drug applications for generic versions of Crestor; and S. 1137, The Patent Act, Technical corrections to the Leahy-Smith American Invents Act and other improvements, provisions in Section 14 relating to the inter partes review process, including federal policy relating to the use of inter partes review challenges of pharmaceutical and biotechnology patents. HOUSE OF REPRESENTATIVES,SENATE   230000 0 0 2016-07-18T18:14:24.943000-04:00
1847683 THE MATHIS HARPLE GROUP df04e325-4651-461f-bad2-1fb3ac058d26 Q2 THE MATHIS HARPLE GROUP 322911 PILMA 2016 second_quarter PHA Patent Protection; 12 Year Data Exclusivity; TPP HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-07-18T18:45:00.103000-04:00
1847930 THORN RUN PARTNERS 31315aad-6294-4335-9a48-a39666db62b9 Q2 THORN RUN PARTNERS 400534596 EXPRESS SCRIPTS, INC. 2016 second_quarter PHA H.R.244, MAC Transparency Act; pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. S.2943/H.R.4909, National Defense Authorization Act for Fiscal Year 2017; provision authorizing a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-07-18T22:42:59.460000-04:00
1847983 NOVO NORDISK INC. fc0c0ed0-1243-4649-91c3-694b07e4ea97 Q2 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2016 second_quarter PHA P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Indian Health Service,Labor, Dept of (DOL),Natl Institutes of Health (NIH),SENATE,Treasury, Dept of   690000 0 0 2016-07-18T23:50:11.297000-04:00
1848610 AMERICAN VETERINARY MEDICAL ASSOCIATION 2c69cbdb-c866-4ac2-8e35-30ca14413318 Q2 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2016 second_quarter PHA Discussions with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230 H.R. 3174/S. 1200, the Fairness to Pet Owners Act (Veterinary Compounding Legislation.) Discussions with DEA regarding use of controlled substances by veterinary practitioners. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE   200000 0 0 2016-07-19T09:17:18.740000-04:00
1848710 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 63112824-6b7f-4623-a93d-8606bd58edf4 Q2 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2016 second_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Extended Producer Responsibility/Pharmaceutical Stewardship (Drug Take-Back) H.R. 4931 - Pharmaceutical Stewardship Act of 2016. Requires the Drug Enforcement Administration to establish and implement a national pharmaceutical stewardship program to collect and dispose of prescription medications; all sections. H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016 (COARA). Amends the Omnibus Crime Control and Safe Streets Act of 1968 to authorize the Attorney General to make grants to assist State and local governments in addressing the national epidemic of opioid abuse, and for other purposes (all sections). S. 524 - Comprehensive Addiction and Recovery Act of 2016 (CARA). Authorizes the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes (Section 201 - expands eligible uses of grant funds to include drug take-back efforts; Section 203 requires coordination among multiple government agencies to develop a prescription drug take-back program). Oral Contraceptives H.R. 5138 - Over-the-Counter Contraceptives Act of 2016. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. H.… Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   280000 0 0 2016-07-19T09:42:23.713000-04:00
1848995 PRIME THERAPEUTICS d2cedf17-4b57-4837-aafa-68d13ead1774 Q2 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2016 second_quarter PHA S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-in, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes. S.2615: the Increasing Competition in Pharmaceuticals Act. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2016-07-19T10:18:56.467000-04:00
1849211 BROWN RUDNICK LLP 2d92dbd8-da15-47f0-9466-1979383c1419 Q2 BROWN RUDNICK LLP 287895 PRIME THERAPEUTICS 2016 second_quarter PHA HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA) Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-19T10:41:21.533000-04:00
1849229 BROWN RUDNICK LLP 0223fb13-1f60-44cf-a7e2-d343bc690d42 Q2 BROWN RUDNICK LLP 287895 EXELA HOLDINGS, LLC 2016 second_quarter PHA Federal policy relating to pharmaceutical pricing and FDA application review protocols Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-07-19T10:43:31.690000-04:00
1849253 BROWN RUDNICK LLP eb0deac6-ddca-4a1b-9b37-d9a488dc84d7 Q2 BROWN RUDNICK LLP 287895 AMNEAL PHARMACEUTICALS 2016 second_quarter PHA HR 4981 -Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4976 - Opioid Review Modernization Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA) HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-07-19T10:45:48-04:00
1849460 RUBICON ADVISORS, LLC cfd9bef4-87fe-4f97-b0d2-c46248f9074d Q2 RUBICON ADVISORS, LLC 315091 TEVA PHARMACEUTICALS USA 2016 second_quarter PHA 21st Century Cures Act HOUSE OF REPRESENTATIVES,SENATE 105000   0 0 2016-07-19T11:06:40.130000-04:00
1849494 RUBICON ADVISORS, LLC b839e714-adb5-4f9d-b762-a9533ed7b1d7 Q2 RUBICON ADVISORS, LLC 315091 OFFICE OF GOVERNOR NATHAN DEAL 2016 second_quarter PHA Pharmaceuticals HR 707, Restoration of America's Wire Act HOUSE OF REPRESENTATIVES,SENATE 43750   0 0 2016-07-19T11:08:59.020000-04:00
1849545 RUBICON ADVISORS, LLC d3c5381b-122c-42f9-9c67-2564a762b740 Q2 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2016 second_quarter PHA Pharmaceuticals HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-07-19T11:13:37.427000-04:00
1849565 RUBICON ADVISORS, LLC c8552669-ad4b-4b49-bf72-b63c37a0cfff Q2 RUBICON ADVISORS, LLC 315091 ALLIANCE TO PREVENT THE ABUSE OF MEDICINES 2016 second_quarter PHA Prescription drug abuse policy HOUSE OF REPRESENTATIVES,SENATE 52500   0 0 2016-07-19T11:14:54.257000-04:00
1849595 RUBICON ADVISORS, LLC 92b07ffd-fd0f-405f-961c-7b044d6e3605 Q2 RUBICON ADVISORS, LLC 315091 COLLEGE OF AMERICAN PATHOLOGISTS 2016 second_quarter PHA Physician Payment Rates, Electronic Health Records Incentives program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-07-19T11:16:17.443000-04:00
1849610 CLOAKROOM ADVISORS LLC 12820600-0b15-4817-8da4-356934f049ca Q2 CLOAKROOM ADVISORS LLC 401103204 LINDEN CARE LLC 2016 second_quarter PHA Congressional delegation outreach and education on issues related to speciality pharmacies HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-19T11:17:29.287000-04:00
1849665 ELI LILLY AND COMPANY 4de7b503-dc24-4a5f-817c-a32bfedee1e2 Q2 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2016 second_quarter PHA Hospital discounts; 340B Program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1840000 0 0 2016-07-19T11:20:06.880000-04:00
1849687 RUBICON ADVISORS, LLC 5efe5505-60e7-4628-9a94-c2551700cc99 Q2 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2016 second_quarter PHA Food and Drug Administration, Generic Drug User Fees, NHI, DEA Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 45000   0 0 2016-07-19T11:21:26.287000-04:00
1849712 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 3d4dd809-7301-4f1b-9e06-f52d0f3cae13 Q2 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 2321 AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES 2016 second_quarter PHA ACA and tax treatment of health care, alternatives to the ACA, ending tax exlusion for employer-provided health care, policies to rein in prescription drug costs NIH march-in rights under Dole-Bayh Act HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Social Security Administration (SSA),Treasury, Dept of,U.S. Trade Representative (USTR),White House Office   650000 0 0 2016-07-19T11:23:46.380000-04:00
1849822 CAPITOL COUNSEL LLC cc70f37c-4ce7-407f-bf9d-32aef03f25e1 Q2 CAPITOL COUNSEL LLC 313715 AMERICAN HEALTH CARE ASSOCIATION 2016 second_quarter PHA S.1560: Nursing Home Resident Pain Relief Act of 2011. S.3604: Improving Dementia Care Treatment for Older Adults Act of 2012. S.621: Safe Prescribing Act. Continued monitoring of Nurse Agent and Drug disposal issue HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2016-07-19T11:29:57.913000-04:00
1850007 HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC 8ae9a86e-6cdf-480e-b7ee-e065be9fe1de Q2 HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC 17966 ELI LILLY AND COMPANY 2016 second_quarter PHA Issues relating to prescription drug prices. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-19T11:46:58.290000-04:00
1850150 RAMPY NORTHRUP LLC b8459cd1-70d7-438d-96f3-0bdcbb0be554 Q2 RAMPY NORTHRUP LLC 401103289 ACADEMY OF MANAGED CARE PHARMACY 2016 second_quarter PHA Dissemination of pharmacoeconomic information. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-19T12:01:26.887000-04:00
1850399 KOUNTOUPES DENHAM CARR & REID, LLC 6615965d-6462-448d-b24f-fc293905b3af Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2016 second_quarter PHA General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. Issues related to H.R. 6, "21st Century Cures" and the Senate Medical Innovations package. Issues related to the over the counter drug monograph process. Issues related to the disposal of unused over the counter drugs. Issues related to the FDA regulatory process by which prescription medicines are switched to Over the Counter. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-07-19T12:23:36.233000-04:00
1850759 BROWN RUDNICK LLP 081c0b5e-f5bf-4bca-8eed-86dd6c65a5e3 Q2 BROWN RUDNICK LLP 287895 HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC 2016 second_quarter PHA S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 524 Comprehensive Addiction and Recovery Act (CARA); H.R. 5046- Comprehensive Opioid Abuse Reduction Act of 2016: H.R. 4641 relating to the establishment of an inter-agency task force on best practices for pain management and prescribing HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-07-19T13:06:26.257000-04:00
1850936 TCH GROUP, LLC fa7be526-e5a2-4246-b5e4-be8b9e2d425b Q2 TCH GROUP, LLC 51478 CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2016 second_quarter PHA S.483, Ensuring Patient Access and Effective Drug Enforcement Act of 2015 HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-07-19T13:27:20.740000-04:00
1851420 AVENUE SOLUTIONS b9538182-15e4-4abf-839c-6ae8f97c785b Q2 AVENUE SOLUTIONS 72111 JAZZ PHARMACEUTICALS, INC. 2016 second_quarter PHA S. 3056, Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES Act of 2016) HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-07-19T14:17:27.373000-04:00
1851464 ISEMAN & ASSOCIATES LLC 46e26da3-f65b-4531-9b63-a09d464ab160 Q2 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2016 second_quarter PHA Monitoring biotech legislation HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-07-19T14:22:07.843000-04:00
1851468 AVENUE SOLUTIONS fbb2f94f-b2a0-4b64-808c-d567d349ee28 Q2 AVENUE SOLUTIONS 72111 MOMENTA PHARMACEUTICALS, INC. 2016 second_quarter PHA issues related to biogenerics and Medicare reimbursement HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-07-19T14:23:14.030000-04:00
1851480 AVENUE SOLUTIONS d3c9fb26-0b4d-49cc-a52a-e5b7a784e890 Q2 AVENUE SOLUTIONS 72111 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 2016 second_quarter PHA issues related to biosimilars; H.R. 6, 21st Century Cures Act   80000   0 0 2016-07-19T14:25:24.453000-04:00
1851907 340B HEALTH 0b904349-34ab-4e97-8466-fca4947ef8a4 Q2 340B HEALTH 316434 340B HEALTH 2016 second_quarter PHA The 340B Drug Pricing program, Health Resources and Services Administration 340B Drug Pricing Program Omnibus Guidance, FY17 Labor Health and Human Services Appropriations, Delaware Medicaid State Plan Amendment, CMS Medicaid and CHIP Managed Care Final Rule, CMS Covered Outpatient Drug Final Regulation,340B Ceiling Price and Manufacturer Civil Monetary Penalties Regulation, Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates,Part B Drug Payment Model Proposed Rule Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   193496 0 0 2016-07-19T14:59:38.567000-04:00
1852264 TEVA PHARMACEUTICALS USA, INC. ba02f505-c0d5-4ac9-b415-aa49c4927dec Q2 TEVA PHARMACEUTICALS USA, INC. 76695 TEVA PHARMACEUTICALS USA INC 2016 second_quarter PHA Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)   930000 0 0 2016-07-19T15:26:38.647000-04:00
1852334 ARNOLD & PORTER KAYE SCHOLER LLP 507a1899-8923-42ed-a01d-91debcc6dc73 Q2 ARNOLD & PORTER KAYE SCHOLER LLP 4301 INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS 2016 second_quarter PHA Issues related to the regulation of the practice of pharmacy compounding. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-07-19T15:33:45.133000-04:00
1852603 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) d396bc14-1e83-4308-8452-98d2dee9b1fb Q2 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2016 second_quarter PHA Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953, H.R. 4641); 21st Century Cures (H.R. 6); Importation of Prescription Drugs (S. 122, H.R. 2228) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   306000 0 0 2016-07-19T16:01:55.557000-04:00
1852826 ASSOCIATION FOR ACCESSIBLE MEDICINES 04883984-327c-45e8-858d-f6df6bfaad37 Q2 ASSOCIATION FOR ACCESSIBLE MEDICINES 16032 ASSOCIATION FOR ACCESSIBLE MEDICINES 2016 second_quarter PHA Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendments (GDUFA). Labeling of Generic Drugs. Biosimilars Naming. Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products. Prescription Drug Costs. H.R.2841: FAST Generics Act of 2015. H.R.1314: Bipartisan Budget Act of 2015. Drug Importation. Risk Evaluation and Mitigation Strategies (REMS). Biologic Exclusivity. Biologics Price Competition and Innovation Act (BPCIA). S.2615: Increasing Competition in Pharmaceuticals Act. Pharmaceutical exclusivity. H.R.4931: Pharmaceutical Stewardship Act of 2016. H.R.953: Comprehensive Addiction and Recovery Act of 2015 (CARA). S.3056: CREATES Act of 2016. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)   802333 0 0 2016-07-19T16:16:23.513000-04:00
1853058 RED+BLUE STRATEGIES 18b5cce0-49f2-404e-942b-0da6787fe176 Q2 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2016 second_quarter PHA S. 524 - the Comprehensive Addition and Recovery Act- issues related to ensuring best prescribing practices for opioids in the country and solutions developed by BCBSMA to combat abuse. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-07-19T16:36:52.017000-04:00
1853199 KOUNTOUPES DENHAM CARR & REID, LLC 0f609380-cf79-4e36-8a28-1a3a2dd8a08a Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2016 second_quarter PHA General education about the pharmacy benefit manager/pharmacy industry. Issues related to H.R. 6, The 21st Century Cures Act and the Senate Innovations for Healthier Americans Initiative. Affordability and pricing of pharmaceuticals and S. 524 The Comprehensive Addiction and Recovery Act of 2015. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-07-19T16:51:46.783000-04:00
1853227 ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA MNK PHARMACEUTICALS) 2752fb55-3b67-4a1e-9cc1-52f09b5ea5cb Q2 ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA MNK PHARMACEUTICALS) 401095056 ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA 2016 second_quarter PHA Highly enriched to Low enriched uranium (HEU-LEU) related issues for Nuclear Medicine (no specific bill number); 21st Century CURES Act (H.R.6); Issues related to "real world" clinical evidence; Issues related to Opioid abuse and alternatives to opioids (no specific bill number). Energy, Dept of,HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE   410000 0 0 2016-07-19T16:55:29-04:00
1853271 MR. GALEN RESER 7795e987-a48c-4db5-beb7-c6b2d8a76008 Q2 MR. GALEN RESER 401055978 PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS) 2016 second_quarter PHA Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-07-19T16:59:16.033000-04:00
1853280 GILEAD SCIENCES, INC. a20d59a4-c7bb-432f-92ef-71c67c32579d Q2 GILEAD SCIENCES, INC. 287177 GILEAD SCIENCES INC 2016 second_quarter PHA Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid and Affordable Care Act implementation; FDA issues and 340B. S. 3056: CREATES Act of 2016. Commerce, Dept of (DOC),Defense, Dept of (DOD),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Veterans Affairs, Dept of (VA)   760000 0 0 2016-07-19T17:00:26-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1844.844ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API